<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385290</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-MOSAIC-075</org_study_id>
    <nct_id>NCT04385290</nct_id>
  </id_info>
  <brief_title>Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II clinical trial evaluates the safety and efficacy of the combined&#xD;
      administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard&#xD;
      chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a&#xD;
      cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or&#xD;
      FMS-like tyrosine Kinase 3 (FLT3) mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients.&#xD;
      Besides age, the genetic configuration of AML blasts is one of the strongest prognostic&#xD;
      factors. Patients with mutations in the core-binding factor (CBF) genes have the best&#xD;
      prognosis, however a considerable proportion of 35-60% will eventually relapse. Mutation and&#xD;
      overexpression of receptor tyrosinkinases (RTK) have been proposed as main reasons for&#xD;
      relapse development or chemoresistance in CBF AMLs. RTKs like stem cell factor receptor&#xD;
      (c-KIT) and FLT3 are of high clinical relevance as they mediate proliferation and&#xD;
      differentiation of hematopoietic stem cells. There is evidence that c-Kit mutations and high&#xD;
      levels of c-KIT in CBF-AML have adverse effects on survival endpoints indicating c-KIT as&#xD;
      potential therapeutic target in this special AML population. Midostaurin can be considered a&#xD;
      potent c-KIT inhibitor besides having multi-kinase inhibitory activity for several other&#xD;
      kinases of documented or potential pathogenetic relevance for AML, most importantly mutated&#xD;
      FLT3. The kinase inhibition ultimately leads to inhibition of proliferation, cell cycle&#xD;
      arrest, and apoptosis. Previous studies with other c-KIT inhibitors such as dasatinib showed&#xD;
      promising results with respect to survival end points in newly diagnosed CBF AML patients.&#xD;
      Midostaurin is considered a more potent c-KIT inhibitor than dasatinib and may be able to&#xD;
      potentiate the inhibitory effect on leukemic cell growth.&#xD;
&#xD;
      Another important therapeutical target in CBF AML is the sialic acid-binding&#xD;
      immunoglobulin-like lectin (CD33) which is expressed on the majority of AML blasts.&#xD;
      Gemtuzumab Ozogamicin (GO) is a therapeutic CD33 antibody linked to a strong cytostatic drug&#xD;
      (calicheamicin) which causes apoptosis of cancer cells upon internalization. For the&#xD;
      combination of GO and standard intensive chemotherapy, metaanalyses of randomized trials have&#xD;
      shown that i) a low-dose fractionated administration results in the best tolerability, and&#xD;
      ii) among AML subgroups, patients with CBF AML have the greatest benefit from GO in addition&#xD;
      to standard therapy. Subgroup analyses within the ALFA-0701 (A Randomized Study of Gemtuzumab&#xD;
      Ozogamicin With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia Aged of&#xD;
      50-70 Years Old) trial population showing beneficial effects of GO on overall survival,&#xD;
      relapse-free survival and event-free survival in patients positive for FLT3 mutation as&#xD;
      compared to those negative for FLT3 mutation. Subgroup analyses of the GO registration trial&#xD;
      ALFA-0701 showed a significant clinical benefit of the patients displaying a mutation in the&#xD;
      FLT3 gene compared to those without this mutation. In Addition, CBF AML patients with FLT3&#xD;
      mutations expressed particularly high levels of CD33 antigen and that CD33 antigen levels&#xD;
      were positively correlated to the improved survival after GO treatment. Furthermore, recently&#xD;
      published data of two paediatric populations with internal tandem mutation in the FLT3 gene&#xD;
      showed reduced relapse rates in GO recipients compared to the control group only receiving&#xD;
      standard chemotherapy. These results suggest that GO is a particularly beneficiary agent in&#xD;
      FLT3 mutated patients who would currently receive midostaurin in addition to intensive&#xD;
      chemotherapy as a standard of care. Hence, from a clinical point of view there is an&#xD;
      unambiguous rationale supporting the combination of midostaurin and GO for treatment of AML&#xD;
      in the two cytogenetic subgroups: CBF AML and FLT3 mutated AML.&#xD;
&#xD;
      GO has become the new treatment standard for patients with CBF AML. The hypothesized positive&#xD;
      effect of midostaurin is likely but randomized proof is laking.&#xD;
&#xD;
      Midostaurin has become the new treatment standard for AML patients with mutations in the FLT3&#xD;
      gene. The positive effect of GO is shown in a post-hoc subgroup analysis of the ALFA-0701&#xD;
      trial, but prospective randomized proof is lacking.&#xD;
&#xD;
      Therefore, the proposed trial intends i) to explore and establish the safe combination of GO&#xD;
      plus midostaurin (MODULE) and ii) to evaluate the effect of midostaurin versus placebo added&#xD;
      to standard AML chemotherapy plus GO in CBF AML (MAGNOLIA) and iii) to evaluate the effect of&#xD;
      GO versus no GO added to standard AML chemotherapy plus midostaurin in FLT3 mutated AML&#xD;
      (MAGMA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Actual">August 13, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The phase I dose escalation trial (MODULE) will be conducted according to the 3+3 design.&#xD;
The phase II trial in CBF AML (MAGNOLIA) will be conducted in a double-blinded and randomized manner.&#xD;
The phase II trial in FLT3 mutated AML (MAGMA) will be conducted in a open label and randomized manner.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Since the trial part MAGNOLIA is designed to be double-blinded, patients, investigators, site personnel, study team members, and anyone involved in the study conduct will remain blinded to the identity of the study drug midostaurin / placebo from the time of randomization until database lock for the primary endpoint analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of midostaurin and GO combination</measure>
    <time_frame>treatment day 8 until day 42 at the latest</time_frame>
    <description>as measured by the number of dose limiting toxicities related to midostaurin or GO exposure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Time interval from date of randomization until either primary treatment failure or relapse or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR/CRi rate</measure>
    <time_frame>after induction treatment, approx. 2 months</time_frame>
    <description>CR/CRi rate is defined as the proportion of patients, who achieved a morphologic complete remission or a complete remission with incomplete hematologic recovery (CR or CRi) during study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of remission</measure>
    <time_frame>after induction treatment, approx. 2 months</time_frame>
    <description>Quantification of measurable residual disease (MRD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Duration of remission is defined as time interval from date of CR/CRi until morphologic relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Cumulative incidence of relapse is defined as the time interval from date of first CR/CRi until relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Relapse-free survival is defined as the time interval from date of first CR/CRi until either morphologic relapse or death in remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Overall survival is defined as time interval from date of randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early mortality rate</measure>
    <time_frame>30 and 60 days after commencement of therapy</time_frame>
    <description>Early mortality is defined as death from any reason within 30 days and 60 days from start of induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (tolerability)</measure>
    <time_frame>until 2 months after commencement of therapy; up to app. 1,5 years after commencement of therapy</time_frame>
    <description>Number and grade of adverse events assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD33 expression of AML blasts</measure>
    <time_frame>after 18 months of study treatment</time_frame>
    <description>Proportion of AML blasts positive for CD33 antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of allogeneic stem cell transplantation</measure>
    <time_frame>up to 5 years from enrolment</time_frame>
    <description>Number of patients with allogeneic stem cell transplantations following response to induction.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>MODULE trial: dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAGNOLIA-trial: conventional chemotherapy+GO and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase II (Trial part MAGNOLIA): placebo is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAGMA-trial: conventional chemotherapy+midostaurin and GO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAGMA-trial: conventional chemotherapy+midostaurin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO</intervention_name>
    <description>Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level&#xD;
GO (IMP) induction: 3 mg/m^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level&#xD;
Daunorubicin (DNR, non-IMP) induction: 60 mg/m^2/day i.v., days 1 to 3&#xD;
Cytarabine (AraC, non-IMP) induction: 200 mg/m^2/day cont. infusion, days 1 to 7</description>
    <arm_group_label>MODULE trial: dose escalation</arm_group_label>
    <other_name>Rydapt</other_name>
    <other_name>Mylotarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO</intervention_name>
    <description>Midostaurin (IMP):&#xD;
RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;&#xD;
GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only&#xD;
Daunorubicin (DNR, non-IMP):&#xD;
60 mg/m^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders&#xD;
Cytarabine (AraC, non-IMP):&#xD;
200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles</description>
    <arm_group_label>MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin</arm_group_label>
    <other_name>Rydapt</other_name>
    <other_name>Mylotarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGNOLIA-trial: Placebo associated with conventional chemotherapy (AraC+DNR)+GO</intervention_name>
    <description>Placebo:&#xD;
peroral, days 8 to 21, 1-2 induction cycles; peroral BID, days 8 to 21, 3 consolidation cycles; peroral BID, days 1 to 28, 12 maintenance cycles;&#xD;
GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only&#xD;
Daunorubicin (DNR, non-IMP):&#xD;
60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders&#xD;
Cytarabine (AraC, non-IMP):&#xD;
200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles</description>
    <arm_group_label>MAGNOLIA-trial: conventional chemotherapy+GO and placebo</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin</intervention_name>
    <description>Midostaurin (IMP):&#xD;
RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;&#xD;
GO (IMP): 3 mg/m^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only&#xD;
Daunorubicin (DNR, non-IMP):&#xD;
60 mg/m^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders&#xD;
Cytarabine (AraC, non-IMP):&#xD;
200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles</description>
    <arm_group_label>MAGMA-trial: conventional chemotherapy+midostaurin and GO</arm_group_label>
    <other_name>Mylotarg</other_name>
    <other_name>Rydapt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin</intervention_name>
    <description>Midostaurin (IMP):&#xD;
RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles&#xD;
Daunorubicin (DNR, non-IMP):&#xD;
60 mg/m^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders&#xD;
Cytarabine (AraC, non-IMP):&#xD;
200 mg/m^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles</description>
    <arm_group_label>MAGMA-trial: conventional chemotherapy+midostaurin</arm_group_label>
    <other_name>Rydapt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Newly diagnosed AML according to the criteria of the World Health Organisation plus&#xD;
             the following molecular or cytogenetic specifications:&#xD;
&#xD;
               -  Phase I Trial - MODULE:&#xD;
&#xD;
                    -  t(8;21)/RUNX1-RUNX1T1 or&#xD;
&#xD;
                    -  inv(16) or t(16;16)/CBFB-MYH11 or&#xD;
&#xD;
                    -  FLT3-ITD or&#xD;
&#xD;
                    -  FLT3-tyrosine kinase domain (FLT3-TKD)&#xD;
&#xD;
               -  Phase II Trial - MAGNOLIA&#xD;
&#xD;
                    -  t(8;21)/RUNX1-RUNX1T1 or&#xD;
&#xD;
                    -  inv(16) or t(16;16)/CBFB-MYH11&#xD;
&#xD;
                    -  FLT3 wild-type&#xD;
&#xD;
               -  Phase II Trial - MAGMA&#xD;
&#xD;
                    -  FLT3-ITD or&#xD;
&#xD;
                    -  FLT3-TKD&#xD;
&#xD;
          -  Male and female patients with age&#xD;
&#xD;
               -  18 - ≤ 75 years in Phase I Trial - MODULE or Phase II Trial - MAGNOLIA&#xD;
&#xD;
               -  18 - ≤ 60 years in Phase II Trial - MAGMA&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Score of 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 14 days&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
               -  alanine aminotransferase / aspartate transaminase ≤ 2.5 x ULN&#xD;
&#xD;
               -  Bilirubin &lt; 2 x upper limits of normal&#xD;
&#xD;
               -  Creatinine &lt; 1.5 x upper limits of normal or Creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
          -  White blood cell count &lt; 30 × 10^9/L. Note: Hydroxyurea is permitted to meet this&#xD;
             criterion.&#xD;
&#xD;
        Exclusion Criteria (all study parts):&#xD;
&#xD;
          -  Previous antineoplastic treatment for AML other than hydroxyurea&#xD;
&#xD;
          -  Previous treatment with anthracyclines&#xD;
&#xD;
          -  central nervous system involvement&#xD;
&#xD;
          -  Isolated extramedullary AML&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g.,&#xD;
             azacytidine or decitabine)&#xD;
&#xD;
          -  Any investigational agent within 30 days or 5 half-lives, whichever is greater, prior&#xD;
             to day 1. An investigational agent is defined as an agent with no approved medical use&#xD;
             in adults or in pediatric patients&#xD;
&#xD;
          -  Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)&#xD;
&#xD;
          -  Strong CYP3A4/5 enzyme inducing drugs unless they can be discontinued or replaced&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Any other known disease or concurrent severe and/or uncontrolled medical condition&#xD;
             (e.g., cardiovascular disease including congestive heart failure or active&#xD;
             uncontrolled infection) that could compromise participation in the study&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that might alter&#xD;
             significantly the absorption of midostaurin&#xD;
&#xD;
          -  Confirmed diagnosis of HIV infection or active viral hepatitis&#xD;
&#xD;
          -  Cardiovascular abnormalities, including any of the following:&#xD;
&#xD;
               -  History of myocardial infarction, angina pectoris, Coronary Artery Bypass&#xD;
                  Grafting within 6 months prior to starting study treatment&#xD;
&#xD;
               -  Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia),&#xD;
                  complete left bundle branch block, high-grade atrioventricular block (e.g.,&#xD;
                  bifascicular block, Mobitz type II and third degree atrioventricular block)&#xD;
&#xD;
               -  Uncontrolled congestive heart failure&#xD;
&#xD;
               -  Left ventricular ejection fraction of &lt; 50%&#xD;
&#xD;
               -  Poorly controlled arterial hypertension&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they fulfill at least one of the following criteria:&#xD;
&#xD;
               -  Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with&#xD;
                  serum follicule stimulating hormone &gt; 40 U/ml)&#xD;
&#xD;
               -  Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without&#xD;
                  hysterectomy&#xD;
&#xD;
               -  Women of childbearing potential must have a negative serum pregnancy test&#xD;
                  performed within 7 days before the first dose of study drug&#xD;
&#xD;
               -  Continuous and correct application of a contraception method with a Pearl Index&#xD;
                  of &lt; 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from&#xD;
                  initial study drug administration until at least 7 months after the last dose of&#xD;
                  gemtuzumab ozogamicin and at least 4 months after the last dose of midostaurin,&#xD;
                  whichever period is longer. A hormonal contraception method must always be&#xD;
                  combined with a barrier method (e.g. condom)&#xD;
&#xD;
               -  Sexual abstinence&#xD;
&#xD;
               -  Vasectomy of the sexual partner&#xD;
&#xD;
          -  Sexually active males unless they use a condom during intercourse while taking the&#xD;
             drug during treatment, and for at least 4 months after stopping treatment and should&#xD;
             not father a child in this period. A condom is required to be used also by&#xD;
             vasectomized men as well as during intercourse with a male partner in order to prevent&#xD;
             delivery of the drug via semen&#xD;
&#xD;
          -  Unwillingness or inability to comply with the protocol&#xD;
&#xD;
          -  Known hypersensitivity to midostaurin, GO, cytarabine or daunorubicin or to any of the&#xD;
             excipients of midostaurin/placebo, GO, cytarabine or daunorubicin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Röllig, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität Dresden, Medical Faculty Carl Gustav Carus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LMU Klinikum, Campus Großhadern, Medizinische Klinik u. Poliklinik III</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR), Klinik f. Hämatologie u. Stammzelltransplantation</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim gGmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg-Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.sal-aml.org/ueber-uns/einfuehrung-ueberblick</url>
    <description>homepage of study group</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>FLT3 mutation</keyword>
  <keyword>CBF</keyword>
  <keyword>midostaurin</keyword>
  <keyword>gemtuzumab ozogamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

